Articles |
From the Department of Hematology, University Hospital, Utrecht, Netherlands, and the Division of Hematology-Oncology (R.J.W., R.I.H.), Department of Medicine, Brigham and Women's Hospital, Boston, Mass.
Correspondence to Dr J.J. Sixma, Department of Haematology, University Hospital Utrecht, PO Box 85500, 3508 GA Utrecht, Netherlands. E-mail jsixma@lab.azu.nl.
| Abstract |
|---|
|
|
|---|
Key Words: von Willebrand factor collagen type III platelet adhesion
| Introduction |
|---|
|
|
|---|
The multimeric size of vWF is important for its function. vWF multimers of lower molecular weight show less binding to platelets in the presence of ristocetin14 and less binding to collagen.15 16 In contrast to ristocetin-induced platelet aggregation,17 the support of platelet adhesion to subendothelium by vWF is not dependent on multimeric size. Studies with SpIII, an amino-terminal dimeric proteolytic fragment of vWF, show that this fragment can also support adhesion to collagen.18
In the present study we examined platelet adhesion to purified vWF from flowing blood and compared its characteristics with those of the adhesion of platelets to collagen type III preincubated with vWF. We paid special attention to the role of the multimeric size of vWF.
| Methods |
|---|
|
|
|---|
Characteristics of vWF
vWF was purified from cryoprecipitates by gel filtration on
Sepharose 4B (Pharmacia AB).9 21 vWF in the void volume
was stored at 4°C and used within 2 weeks after purification. The
characteristic pattern of a band at 270 000 and two minor proteolytic
bands at 170 000 and 140 000 kD was found in
SDSpolyacrylamide gel electrophoresis of reduced vWF. In
experiments in which the effect of the multimeric composition
of vWF was studied, separate 3-mL fractions from the Sepharose 4B gel
filtration column were studied for their multimeric
composition, ristocetin cofactor activity, and vWF antigen content.
These fractions were then used for coating coverslips or binding of vWF
to collagen type III.
Determination of the Multimeric Composition of
vWF
The multimeric structure of vWF was assayed by using the
Pharmacia Phast Gel System (Pharmacia LKB Biotechnology) as described
by Lawrie et al.22 Briefly, samples diluted in 10 mmol/L
Tris/HCl, 1 mmol/L EDTA, 2% SDS, 8 mol/L urea, and 0.05% bromophenol
blue, pH 8.0, were applied to a 1.7% agarose gel (LE, Seakem, FMC
Bioproducts) in 0.5 mol/L Tris/HCl, pH 8.8, and 0.1% SDS with
a stacking gel consisting of 0.8% agarose (HGT, Seakem) in 0.125 mol/L
Tris/HCl, pH 6.8, and 0.1% SDS. After electrophoresis the protein was
transferred to a polyvinylidene fluoride membrane (Immobilon P,
Millipore) by diffusion blotting for 1 hour at 60°C. The membrane was
then blocked with 5% nonfat dry milk protein solution (Protifar,
Nutricia) for 1 hour at room temperature. After washing with PBS/T, pH
7.4, the blot was incubated with horseradish peroxidaseconjugated
rabbit polyclonal antibodies to human vWF (Dakopatts) diluted 1:1000 in
PBS/T for 1 hour at room temperature. After three washes with PBS/T,
the membrane was incubated with the substrate solution (25 mg
3,3'-diaminobenzidine tetrahydrochloride [Sigma] in 50 mL PBS
with 10 µL 30% H2O2). The enzyme reaction
was stopped by washing the membrane with distilled water.
vWF-
PRO
vWF-
PRO was synthesized in Chinese hamster ovary cells
transfected with vWF cDNA containing a deleted propeptide-coding
region. Construction of the vWF-
PRO cDNA and establishment of the
Chinese hamster ovary cell line has been described.23 24
Serum-free conditioned medium was collected24 and
concentrated in dialysis bags covered with Aquacide-3 (CalBiochem).
Following concentration and dialysis against 50 mmol/L Tris-HCl (pH
7.6) and 150 mmol/L NaCl, the medium was applied to a Bio-Gel A.5
(Bio-Rad) chromatography column. vWF was collected in
the void volume and concentrated by ultrafiltration.
Coating and Spraying of Coverslips
Glass coverslips (Menzel Gläser, 18x18 mm) were cleaned
overnight by a chromium trioxide solution and rinsed with distilled
water before coating. Coating was performed by incubating the
coverslips with 100 µL purified vWF in PBS for 1 hour followed by a
1-hour incubation with 4% human albumin solution in PBS to
block further protein binding. After coating, coverslips were kept in
PBS until perfusion. The quantity of vWF that was coated to the
coverslip was measured with vWF labeled with 125I by using
lactoperoxidase-glucose-oxidase (Enzymobeads, Bio-Rad)
according to the instructions of the manufacturer. The effect of
radioactive labeling of vWF was checked by mixing different amounts of
labeled and unlabeled protein and keeping the total amount of vWF
constant. No differences in coating behavior were observed, indicating
that radioactive labeling had not affected the adsorption of vWF (data
not shown).
Monomeric collagen type III (acid soluble) was solubilized in 50 mmol/L acetic acid and sprayed with a density of 30 µg/cm2 on glass coverslips with a retouching airbrush (model 100, Badger Brush Co).25 26 After the spraying procedure the collagen surface was incubated for 1 hour with 1% human albumin in PBS to block further protein binding. The surface was then incubated with vWF (10 µg/mL in PBS) for 1 hour at room temperature and washed three times with PBS. Fibronectin was isolated from human plasma by affinity chromatography on gelatin-Sepharose.9 SDSpolyacrylamide gel electrophoresis after reduction showed the characteristic doublet at 220 000 kD. Fibronectin was coated by spraying at a concentration of 20 µg/cm2. In some experiments, vWF solubilized in PBS was sprayed in the same way as collagen type III or fibronectin. After the spraying procedure, vWF or fibronectin was blocked with 1% human albumin in PBS by incubation for 1 hour.
Human endothelial cells derived from umbilical veins were isolated and cultured27 28 on glass coverslips previously coated with gelatin. To isolate the extracellular matrix, cells were grown to confluence and exposed to 0.1 mol/L NH4OH for 30 minutes at room temperature. The cell layer was completely removed by this procedure, leaving the extracellular matrix intact.29 The extracellular matrix was washed three times with PBS before use.
Perfusion Studies
Perfusion studies were performed in a parallel-plate
perfusion chamber with well-defined rheologic characteristics
devised to accommodate duplicate protein-coated glass
coverslips.30 Whole blood obtained by
venipuncture from healthy volunteer donors was
anticoagulated with 1:10 vol 110 mmol/L trisodium citrate (citrated
blood) or with 1:10 vol 200 U/mL LMWH. Whole blood (15 mL) was
prewarmed at 37°C for 5 minutes and recirculated through the
perfusion chamber for 5 minutes at wall shear rates ranging from 300 to
1800 s-1. The coverslips were removed,
rinsed with 10 mmol/L HEPES buffer (pH 7.4) containing 150 mmol/L NaCl,
fixed in 0.5% glutaraldehyde, dehydrated in methanol,
and stained with May-Gruenwald-Giemsa.31 Platelet
adhesion was evaluated by using light microscopy, and the coverage was
measured with an image analyzer (AMS 40-10). Adhesion was
expressed as the percentage of the surface covered with
platelets.
For the perfusion studies over collagen preincubated with vWF,
reconstituted blood was used that was prepared as follows.
Platelet-rich plasma was obtained from whole blood by
centrifugation (10 minutes at 200g and
20°C). One volume of Krebs-Ringer buffer (in mmol/L: KCl 4, NaCl 107,
NaHCO3 20, and Na2SO4 2, pH 5.0)
containing 19 mmol/L sodium citrate was added to 1 vol
platelet-rich plasma (final pH
6). A platelet pellet was
obtained by centrifugation (10 minutes at
500g and 20°C). The platelet pellet was resuspended in
Krebs-Ringer buffer, pH 6.0, and washed twice by
centrifugation (10 minutes at 500g). After
the second wash, platelets were resuspended to a platelet count
of 190 000/µL in a human albumin solution (4% human
albumin in Krebs-Ringer buffer without citrate, pH 7.35,
containing 20 U/mL LMWH, 5 mmol/L
-D-glucose, and 2.5
mmol/L CaCl2). Red cells were washed three times with PBS
containing 5 mmol/L
-D-glucose (2000g at
20°C, twice for 5 minutes and the last time for 15
minutes).9 Washed red cells were added in a volume
fraction of 40% of total volume 5 minutes before perfusion.
To reach higher shear rates, platelet adhesion was studied by using square glass microcapillaries (Microcell, The Wilmad Glass Co Inc). The glass microcapillaries were coated by adsorption of vWF as described for the coverslips. Perfusions were performed with a single passage, drawing blood from a container through the tube at the appropriate speed by using a syringe and an automated syringe pump (Harvard Apparatus).
The studies with vWF-
PRO were performed with a specially devised
small perfusion chamber (in mm: width 2, length 18, and height 0.1).
Because of the limited availability of vWF-
PRO, a template was
prepared that allowed spraying of the area of the coverslip that was
exposed to the flowing blood. Perfusions were performed with a single
passage by using aspiration with a pump-driven syringe as described
above. Flow rates varied from 0.1 to 0.8 mL/min during 5 minutes.
Platelet adhesion was evaluated by using light microscopy and an
image analyzer as described above. Evaluation was in 12 fields
perpendicular to the flow rate in the middle of the chamber, 12 fields
3 mm upstream, and 12 fields 3 mm downstream (magnification
x1000).
SEM
For SEM, coverslips with platelets fixed for 1 hour with 2%
glutaraldehyde at room temperature were postfixed in
1% osmium tetroxide for 1 hour, dehydrated in a graded series of
ethanols, and dried by the critical-point procedure with
CO2 as transitional fluid. The samples were sputter coated
with a thin layer of gold and viewed in an SEM (Cam Scan S2).
| Results |
|---|
|
|
|---|
60
ng/cm2 vWF on the glass coverslip. Because proteins
adsorbed to a surface will denature with time, the effect of time after
adsorption on platelet adhesion was studied. Platelet adhesion
to a vWF-coated surface started to decrease after 6 hours of storage at
room temperature. After 48 hours of storage, platelet adhesion was
decreased to 50% of the adhesion value after 2 hours of storage (data
not shown). The role of vWF present in the blood was tested by
comparing adhesion from whole blood with adhesion from reconstituted
blood in which plasma was replaced by a human albumin solution.
No difference in adhesion was observed (results not shown).
|
|
Time Dependence
The adhesion of platelets to vWF was studied at 1, 3, 5, 10,
and 15 minutes at shear rates of 300, 1000, and 1500
s-1 (Fig 3
, top). Fast
initial platelet adhesion was found in the first minute followed by
a more or less linear phase between 1 and 5 minutes. The increase in
adhesion gradually declined between 5 and 15 minutes. This pattern of
time dependence differed from that of platelet adhesion to
fibronectin, collagen type III at 300 s-1
and 1500 s-1, and collagen type
IV, which showed a linear phase in the first 10 minutes but
corresponded closely to that observed on ECM (Fig 3
, bottom).
|
Shear Rate Dependence
vWF is regarded as specifically suited for adhesion interactions
at high shear rates. The perfusion system that is used in most studies,
the parallel-plate perfusion system of Sakariassen et
al,30 is not suited for perfusions at very high shear
rates (>2600 s-1). We therefore used
square glass microcapillaries through which blood was aspirated from a
container at 37°C with a pump-driven syringe. Comparison studies
with the parallel-plate perfusion system were first performed.
These studies showed no essential difference between platelet
adhesion in a single-passage system and a system with repeated
recirculation of blood (results not shown). The shear rate dependence
of platelet adhesion over a large range of shear rates is shown in
Fig 4
. Adhesion to vWF did not decrease at higher shear
rates (up to 4000 s-1), in contrast to
adhesion to fibronectin, laminin, and thrombospondin, which show
optimal adhesion at 300, 800, and 1500
s-1,
respectively.32 33 34
|
Several studies that used platelet-rich plasma or platelets
in vWF-containing buffer have shown that platelets aggregate under
high shear rate conditions in a plate-and-cone
viscometer.35 36 This aggregation is dependent on the
GPIb-vWF interaction, which at high shear stress may
activate platelets.36 37 38 We tried to discern
whether this mechanism occurs in whole blood during flow at high shear
rates. Adhered platelets showed dendritic and spread forms (Fig 5
). There was more pronounced spreading of platelets
adhering at the highest shear rate (4000
s-1; Fig 5c
) than at lower shear rates of
300 (Fig 5a
) and 1000 (Fig 5b
)
s-1, but no or only small
aggregates were observed, apart from single dendritic cells lying on
top of thin, fully spread platelets. We also studied adhesion at
4000 s-1 at 1 and 3 minutes to ascertain
that no aggregates had been present that were subsequently swept
away. No aggregates were observed at these earlier times. We also
studied platelet adhesion to vWF at 4000
s-1, using
hirudin-anticoagulated blood, to see whether aggregate formation
might occur under these conditions. Again, no aggregates were
observed.
|
Multimeric Composition
Unlike ristocetin-induced platelet
aggregation,17 vWF-dependent platelet adhesion to
subendothelium is not influenced by the
multimeric size of vWF. In the present study we considered
the effect of multimeric size on platelet adhesion to
purified vWF. Different 3-mL fractions from gel filtration purification
of vWF were collected separately. Coverslips were adsorbed with these
various samples at 10 µg/mL as described above, and platelet
adhesion at 1000 s-1 was estimated. Fig 6
(top) presents a curve in which the percent
surface coverage is plotted against the column fraction. There was a
gradual decrease in platelet adhesion with lower molecular weights.
The multimeric distribution present in the various
fractions is also shown (Fig 6
, bottom). To exclude the possibility of
different adsorption of various multimers leading to
differences in adhesion, we also coated glass coverslips by spraying
the different multimeric fractions onto the coverslips. A
similar decrease in adhesion with decreasing multimeric size
was observed (data not shown).
|
To obtain further insight into the role of the multimeric
structure of vWF, we studied adhesion to dimeric vWF. The vWF-
PRO
molecule forms dimers but fails to multimerize because it is
synthesized in the absence of the vWF propeptide.23 39 We
first performed a concentration dependence study by spraying vWF-
PRO
on a coverslip (Fig 7
, top). Higher concentrations of
vWF-
PRO than of plasma vWF were required (Fig 2
) to obtain
optimal adhesion, and adhesion to vWF-
PRO was lower. A time curve of
adhesion to vWF-
PRO shows the same initial fast adhesion as that
observed with plasma vWF (data not shown; see Fig 3
). Adhering
platelets were less spread than on multimeric vWF and
tended to form lateral aggregates (Fig 5d
). After 10 minutes definite
aggregate formation had occurred. Since a special perfusion procedure
had been used to minimize the consumption of recombinant vWF-
PRO, we
also studied adhesion to plasma vWF by using this system. No aggregate
formation was observed, and platelet adhesion was similar to that
which was observed with the other perfusion systems. The adhesion to
vWF-
PRO showed an increase, with the shear rate up to 1500
s-1 (Fig 7
, bottom). A gradual decrease
occurred at higher shear rates, in contrast to that which was observed
with plasma vWF.
|
Modulation of Adhesion to vWF
Divalent cations. The effect of divalent cations on the
adhesion to vWF was tested by comparing perfusions performed with
citrated blood and blood anticoagulated with a mixture of hirudin 20
U/mL and PPACK 30 nmol/L. Similar values were found in two separate
duplicate experiments, indicating that divalent cations at plasma
concentrations are not required for adhesion to vWF. vWF-dependent
adhesion to the subendothelium of umbilical
arteries is inhibited by treatment of vWF with EDTA.40 In
the present study vWF was adsorbed to glass and then treated with
EDTA. Treatment with EDTA gave only a weak inhibition of adhesion
(Table 1
).
|
Heparin. Adhesion of platelets to GPIb-binding
fragments of vWF is inhibited by heparin.41 We studied
whether heparin had any effect on adhesion to vWF in two different ways
(Table 2
). In one set of experiments unfractionated
heparin or LMWH was added in different concentrations to citrated
blood, and adhesion from these samples was compared. Heparin addition
yielded a concentration-dependent inhibition of platelet
adhesion. LMWH had less effect. In a second set of experiments,
adsorbed vWF was preincubated with unfractionated heparin or LMWH; this
preincubation was followed by perfusion studies in which citrated blood
was circulated over the incubated surfaces. Preincubation of vWF with
heparin caused a somewhat stronger inhibiting effect than addition of
heparin to blood (51.8% of control versus 62.3% at 5 U/mL). Addition
of LMWH had less effect (Table 2
).
|
Effect of prostacyclin. Prostacyclin was added to whole
blood 5 minutes before recirculation of the blood through
the perfusion system. A concentration-dependent inhibition of
platelet adhesion was observed, with half-maximal adhesion at
0.5 ng/mL (Fig 8
).
|
Platelet Receptors for Adhesion to vWF
Platelets have two receptors for vWF, the GPIb-IX complex and
the GPIIb-IIIa complex.42 We have studied the involvement
of these two receptors in adhesion to vWF in flow by using monoclonal
antibodies to both receptors. Powerful inhibition was found with
anti-GPIb as well as with antiGPIIb-IIIa antibodies (Fig 9
), indicating that both receptors are involved in
adhesion to vWF.
|
Role of vWF in Platelet Adhesion to Collagen Type
III
Because adhesion of blood platelets to collagen in flow is
mediated by vWF,9 we also studied the role of various
variables of vWF-mediated adhesion to collagen type III. Adhesion
showed time dependence, with a more or less linear increase in adhesion
over 15 minutes at 300 s-1 and a somewhat
more rapid increase in the first minute at 1500
s-1, which was less rapid than the
results found for vWF at all shear rates (Fig 3
). The effect of the
shear rate on platelet adhesion is shown in Fig 4
. Platelet
adhesion increased slowly between 1000 and 4000 s
-1, similar to that for vWF alone.
Fig 4
also shows the shear rate dependence of adhesion to ECM, which is
also vWF dependent. This adhesion follows a similar pattern as adhesion
to vWF alone or vWF-mediated adhesion to collagen type III. As in the
case of adhesion to vWF alone, preincubation of vWF with EDTA had no
effect (data not shown). Platelet adhesion was also not
significantly affected by the addition of 5 U/mL unfractionated heparin
to citrated blood (results not shown). The role of the
multimeric size of vWF was studied by preincubating collagen
type III with various fractions obtained from the gel filtration
purification of vWF (Fig 6
), similar to those used for the study of the
influence of multimeric structure on platelet adhesion to
vWF described above. The effect of multimeric size tended to be
less gradual than that for vWF alone. There was no effect in the two
higher molecular weight fractions and a relatively steep decline in the
two lower molecular weight fractions. The effect of prostacyclin on
vWF-dependent adhesion to collagen type III is shown in Fig 8
. A degree
of inhibition by prostacyclin similar to that occurring when vWF alone
was the adhesive molecule was found. The role of the platelet
receptors GPIb and GPIIb-IIIa was studied by using monoclonal
antibodies (Fig 9
). Anti-GPIb gave complete inhibition of adhesion.
AntiGPIIb-IIIa also inhibited adhesion, but more antibody was
required, and the dose-response curve was flatter than for vWF
alone.
| Discussion |
|---|
|
|
|---|
Adsorption of radiolabeled vWF to glass coverslips was linear with a
concentration below 50 µg/mL. This agrees well with data showing
saturation near concentrations of 200 µg/mL when glass capillaries
are incubated with vWF (Table 1
). The amount of vWF that bound also
accords with reported data.12 Platelet adhesion to the
coated coverslips reached a maximum, however, before the surface was
saturated with vWF. Maximum adhesion was reached at 10 µg/mL, which
corresponded to a surface binding of 60 ng/cm2. No increase
in adhesion was seen at higher surface concentrations. The data
obtained with adsorbed vWF were compared with those obtained with vWF
sprayed on the surface. This technique is the preferred one for many
adhesive proteins. It has as a major advantage in that the amount of
protein present on the surface is precisely known. A maximum
adhesion equivalent to that obtained with adsorbed vWF was found at 3
µg/cm2. Since 60 ng/cm2 of adsorbed vWF gave
optimal adhesion, only 2% of sprayed material appears to be reactive.
Whether this is due to denaturation resulting from the spraying or the
air drying is not clear. What is evident, however, is that the
denaturation is an all-or-nothing phenomenon in view of the
excellent adhesion to the sprayed material. The time-dependent
adhesion of platelets to vWF shows a fast initial attachment that
is not seen with other adhesive proteins. Why adhesion levels off after
this first minute is not clear. This cannot be due to coating of the
surface with plasma proteins because the vWF has been blocked with a
human albumin solution. Nor can it be due to saturation of the
surface with platelets, because this tends to occur at surface
coverages between 60% and 80% and is common to all adhesive proteins.
The fast initial attachment was also observed for ECM and to a lesser
extent for collagen type III at 1500
s-1, which is in agreement with
the hypothesis that the vWF-GPIb interaction is responsible for the
rapid initial attachment of platelets to
subendothelium.49
The shear rate dependence of the adhesion to vWF shown here gives a slight but continuous increase in adhesion, with a shear rate of up to 4000 s-1. This is not identical to previous data in the capillary system that show a leveling off above 2000 s-1,12 but more experimental points at high shear rates were studied in the present investigation. The main point of the effect of shear is that adhesion to vWF and vWF-dependent adhesion to ECM and collagen types I and III are the only situations that show no decrease at high shear rates. This suggests that there is a difference in resistance to shear stress between adhesion to vWF and vWF-dependent adhesion to collagen or ECM on the one hand and adhesion to other adhesive molecules on the other.
Platelets aggregate under high shear stress (>30 dynes/cm2=3 Pa), such as that attained in a plate-and-cone viscometer in dependence of vWF.35 36 This interaction is mediated by GPIb and leads to activation of platelets followed by exposure of GPIIb-IIIa and interaction of vWF with this receptor.37 38 The interaction is particularly mediated by high-molecular-weight vWF multimers.35 We wondered whether this would also occur in whole blood. The shear stress values that are attained in the microcapillary system at a shear rate of 4000 s-1 are on the order of 16 Pa when one assumes the viscosity of blood to be 4 mPaxs. This is probably not correct in small tubes, where there is a plasma layer near the vessel wall due to the Fahraeus-Lindqvist effect50 in which platelets are concentrated. If one calculates the shear stress with a plasma viscosity of 1.1 mPaxs, a shear stress of 4.4 Pa is obtained, which is still in the range found to give platelet aggregation in the plate-and-cone viscometer. It is thus surprising that we did not observe aggregates in our studies, as a possible activating effect of the vWF-GPIb interaction should be further enhanced by the platelet spreading on the surface, which also causes platelet activation. High shear stress may have a different effect on vWF-mediated platelet-platelet interaction than on platelet-substrate interaction.
We have reported that chelation of calcium with either EDTA or EGTA causes a change in function of vWF in supporting adhesion to subendothelium but not in ristocetin-induced aggregation,40 but we could not reproduce that finding in the current studies. Incubation of adsorbed vWF with chelating agents had almost no effect on its function. We also checked whether preincubation of vWF in solution with EDTA followed by adsorption from this solution would give a loss in function (data not shown), but this had no effect. We have no explanation for this discrepancy. One possibility that requires further study is that calcium is involved in binding of vWF to subendothelium, a mechanism that involves a substrate other than collagen types I and III.45 48
When we studied the effect of divalent cations we found an effect of heparin that caused a decrease in platelet adhesion to vWF. Further studies showed that preincubation of adsorbed vWF with heparin caused this inhibition. The addition of unfractionated heparin to citrated blood also had this inhibitory effect but to a lesser extent. These studies suggest that heparin from blood binds to vWF and causes an inhibition of interaction with platelets. The existence of such a mechanism is supported by studies that localize the heparin-binding domain of vWF between residues 565 and 587 of the A1 repeat,51 which is responsible for GPIb binding as well as for all heparin binding52 and is in agreement with studies53 that show that heparin inhibits binding of vWF to platelets in the presence of ristocetin or botrocetin and platelet agglutination caused by bovine vWF or asialo-vWF. The lesser inhibitory effect of LMWH may be due to lower binding affinity but may also be due to a less pronounced steric effect caused by its shorter mean chain length. Why heparin does not have this inhibitory effect on platelet adhesion to collagen type III or to ECM (Y.-P.W., J.J.S., P.G. de G., unpublished data, 1993) is unclear. It could be explained if one assumes that heparin interferes with the interaction with GPIIb-IIIa, which is less important on collagen and ECM. However, the heparin-binding site on vWF is not localized near the RGD sequence on residues 1744 through 1747, which is responsible for the interaction with GPIIb-IIIa.
The effect of the multimeric size differed when adhesion to
adsorbed vWF or preincubation of collagen type III was studied.
Adhesion to adsorbed vWF showed a gradual decrease with a decreasing
molecular weight, whereas adhesion to collagen showed a more abrupt
decrease in the two lowest fractions. This last effect may be due to
the fact that platelet vWF released by collagen may participate in
adhesion to collagen7 8 and thus make it less sensitive to
the composition of exogenous vWF. Carboxy-terminal
disulfide-bonded dimers of vWF were generated by expressing
vWF-
PRO in Chinese hamster ovary cells. Higher surface
concentrations of this vWF were required for adhesion, which was less
extensive and had notably less spreading than plasma vWF. The initial
fast adhesion that is characteristic of vWF was also seen with the
dimeric form, but adhesion was less resistant to shear stress,
although considerable adhesion was still present at 4000
s-1. These data indicated that the
multimeric structure of vWF has a definite function in
platelet adhesion, with 50% reduction with the lowest molecular
weight multimers. The adhesion found with vWF-
PRO in the
current study and with a proteolytic dimeric fragment30
contradicts the absence of adhesion found with vWF type 2A. The low
molecular weight of the multimers is thought to be caused by
proteolytic cleavage of vWF in at least half the cases,54
but these multimers are not functional. This discrepancy
requires further study.
A curious phenomenon was the presence of aggregates occurring on
vWF-
PRO but not on plasma vWF after >10 minutes of perfusion at
1000 s-1. The studies were performed with
the single-pass system, which excludes platelet activation due
to recirculation. The shear stress was also less than the 3 Pa required
to cause aggregation with high-molecular-weight
multimers in the plate-and-cone viscometer discussed
above. We have no explanation for this unusual result.
We studied the participation of GPIb and GPIIb-IIIa in adhesion to vWF
by using monoclonal antibodies. Both antibodies gave pronounced
inhibition (Fig 9
). AntiGPIIb-IIIa was less effective on
vWF-dependent adhesion to collagen type III, and the dose-response
curve was flatter. Further studies are required to define their precise
roles. One such study, which uses mutants of vWF with defective
function, is available.55 A role for both GPIb and
GPIIb-IIIa in adhesion to vWF is in agreement with data from Savage et
al11 in a static system and Danton et al13 in
a flow system.
Adhesion was inhibited by prostacyclin at equivalent concentrations
(Fig 8
), whether vWF was directly coated to glass or adsorbed by
preincubation to collagen type III. The effect of prostacyclin was
probably not on the availability of GPIIb-IIIa as the receptor for
ligands because studies with antiGPIIb-IIIa showed differences
between vWF alone and vWF-dependent adhesion to collagen type III.
Prostacyclin is a relatively poor inhibitor of adhesion to
the vessel wall and a better inhibitor of platelet
aggregation.56 The current data show that this may not be
true when a more limited number of adhesive molecules are involved in
adhesion.
| Selected Abbreviations and Acronyms |
|---|
|
Received June 20, 1995; accepted January 5, 1996.
| References |
|---|
|
|
|---|
2.
Weiss HJ, Baumgartner HR, Tschopp TB, Turitto VT,
Cohen D. Correction by factor VIII of the impaired platelet
adhesion to subendothelium in von
Willebrand's disease. Blood. 1978;51:267-279.
3. Baumgartner HR, Tschopp TB, Meyer D. Shear rate dependent inhibition of platelet adhesion and aggregation on collagenous surfaces by antibodies to human factor VIII/von Willebrand factor. Brit J Haematol. 1980;44:127-139. [Medline] [Order article via Infotrieve]
4. Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to the subendothelium. Nature. 1979;279:635-638.
5.
Stel HV, Sakariassen KS, De Groot PG, Van Mourik JA,
Sixma JJ. Von Willebrand factor in the vessel wall mediates
platelet adherence. Blood. 1985;65:85-90.
6.
Turitto VT, Weiss HJ, Zimmerman TS, Sussman II.
Factor VIII/von Willebrand factor in
subendothelium mediates platelet
adhesion. Blood. 1985;65:823-831.
7.
Fressinaud E, Baruch D, Rothschild C, Baumgartner HR,
Meyer D. Platelet von Willebrand factor: evidence
for its involvement in platelet adhesion to collagen.
Blood. 1987;70:1214-1217.
8. D'Alessio P, Zwaginga JJ, de Boer HC, Federici AB, Rodeghiero F, Castaman G, Mariani G, Mannucci PM, de Groot PG, Sixma JJ. Platelet adhesion to collagen in subtypes of type I von Willebrand's disease is dependent on platelet von Willebrand factor. Thromb Haemost. 1990;64:227-231. [Medline] [Order article via Infotrieve]
9. Houdijk WPM, Sakariassen KS, Nievelstein PFEM, Sixma JJ. Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar collagen types I and III. J Clin Invest. 1985;75:531-540.
10.
Hantgan RR, Hindriks G, Taylor R, Sixma JJ, De Groot
PG. Glycoprotein Ib, von Willebrand factor,
and glycoprotein IIb:IIIa are all involved in platelet
adhesion to fibrin in flowing whole blood. Blood. 1990;76:345-353.
11.
Savage B, Shattil SJ, Ruggeri ZM. Modulation of
platelet function through adhesion receptors: a dual role for
glycoprotein IIb-IIIa (integrin
IIbß3) mediated by
fibrinogen and glycoprotein Ib-von Willebrand
factor. J Biol Chem. 1992;267:11300-11306.
12. Olson JD, Zaleski A, Herrmann D, Flood PA. Adhesion of platelets to purified solid-phase von Willebrand factor: effects of wall shear rate, ADP, thrombin, and ristocetin. J Lab Clin Med. 1989;114:6-18. [Medline] [Order article via Infotrieve]
13. Danton MC, Zaleski A, Nichols WL, Olson JD. Monoclonal antibodies to platelet glycoproteins Ib and IIb/IIIa inhibit adhesion of platelets to purified solid-phase von Willebrand factor. J Lab Clin Med. 1994;124:274-282. [Medline] [Order article via Infotrieve]
14. Doucet-de Bruine MHM, Sixma JJ, Over J, Beeser-Visser NH. Heterogeneity of factor VIII: characterization of forms of factor VIII binding to platelets in the presence of ristocetin. J Lab Clin Med. 1978;92:96-107. [Medline] [Order article via Infotrieve]
15. Santoro SA. Preferential binding of high molecular weight forms of von Willebrand factor to fibrillar collagen. Biochim Biophys Acta. 1983;756:123-126. [Medline] [Order article via Infotrieve]
16.
Kessler CM, Floyd CM, Rick ME, Krizek DM, Lee SL,
Gralnick HR. Collagen-factor VIII/von Willebrand
factor protein interaction. Blood. 1984;63:1291-1298.
17.
Sixma JJ, Sakariassen KS, Beeser-Visser NH,
Ottenhof-Rovers M, Bolhuis PA. Adhesion of platelets to
human artery subendothelium: effect of factor
VIII-von Willebrand factor of various multimeric
compositions. Blood. 1984;63:128-139.
18.
Sakariassen KS, Fressinaud E, Girma JP, Baumgartner HR,
Meyer D. Mediation of platelet adhesion to fibrillar
collagen in flowing blood by a proteolytic fragment of human von
Willebrand factor. Blood. 1986;67:1515-1518.
19. Berndt MC, Du X, Booth WJ. Ristocetin dependent reconstitution of binding of von Willebrand factor to purified human platelet membrane GPIb-IX complex. Biochemistry. 1988;27:633-640. [Medline] [Order article via Infotrieve]
20. Tettero PAT, Lansdorp PM, Leeksma OC, von dem Borne AEG. Monoclonal antibodies against human platelet glycoprotein IIIa. Br J Haematol. 1983;55:509-522. [Medline] [Order article via Infotrieve]
21. Van Mourik JA, Mochtar IA. Purification of human anti-hemophilic factor (factor VIII) by gel-chromatography. Biochim Biophys Acta. 1970;221:677-679. [Medline] [Order article via Infotrieve]
22. Lawrie AS, Hoser MJ, Savidge GF. Phast assessment of vWF:Ag multimeric distribution. Thromb Res. 1990;59:369-372. [Medline] [Order article via Infotrieve]
23. Wise RJ, Pittman DD, Handin RI, Kaufman RJ, Orkin SH. The propeptide of von Willebrand factor independently mediates the assembly of von Willebrand multimers. Cell. 1988;52:229-236. [Medline] [Order article via Infotrieve]
24.
Wise RJ, Dorner AD, Krane M, Pitmann DD, Kaufman
RJ. The role of von Willebrand factor multimers
and propeptide cleavage in binding and stabilization of factor
VIII. J Biol Chem. 1991;266:21948-21955.
25. Muggli R, Baumgartner HR, Tschopp TB, Keller H. Automated microdensitometry and protein assay as a measure for platelet adhesion and aggregation on collagen-coated slides under controlled flow conditions. J Lab Clin Med. 1980;95:195-207. [Medline] [Order article via Infotrieve]
26.
Saelman EU, Nieuwenhuis HK, Hese KM, de Groot PG,
Heijnen HF, Sage EM, Williams S, McKeown L, Gralnick HR, Sixma
JJ. Platelet adhesion to collagen types I through VIII under
conditions of stasis and flow is mediated by GPIa/IIa
(
2ß1-integrin). Blood. 1994;83:1244-1250.
27. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745-2756.
28. Willems C, Astaldi GC, De Groot PG, Janssen MC, Gonsalvez MD, Zeijlemaker WP, Van Mourik JA, Van Aken WG. Media conditioned by cultured human vascular endothelial cells inhibit the growth of vascular smooth muscle cells. Exp Cell Res. 1982;139:191-197. [Medline] [Order article via Infotrieve]
29. Sixma JJ, Nievelstein PFEM, Zwaginga JJ, De Groot PG. Adhesion of blood platelets to the extracellular matrix of cultured human endothelial cells. Ann N Y Acad Sci. 1987;516:39-51. [Medline] [Order article via Infotrieve]
30. Sakariassen KS, Aarts PAMM, De Groot PG, Houdijk WPM, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix and purified components. J Lab Clin Med. 1983;102:522-535. [Medline] [Order article via Infotrieve]
31.
Nievelstein PFEM, d'Alessio PA, Sixma JJ.
Fibronectin in platelet adhesion to human collagen types I and III:
use of nonfibrillar and fibrillar collagen in flowing blood
studies. Arteriosclerosis. 1988;8:200-206.
32.
Beumer S, Ijsseldijk MJW, De Groot PG, Sixma JJ.
Platelet adhesion to fibronectin in flow: dependence on surface
concentration and shear rate, role of membrane GP IIb/IIIa and VLA-5
and inhibition by heparin. Blood. 1994;84:3724-3733.
33.
Hindriks GA, Ijsseldijk MJW, Sonnenberg A, Sixma JJ, De
Groot PG. Platelet adhesion to laminin: role of Ca2+ and
Mg2+ ions, shear rate, and platelet membrane
glycoproteins. Blood. 1992;79:928-935.
34. Agbanyo FR, Sixma JJ, De Groot PG, Languino LR, Plow EF. Thrombospondin-platelet interactions: role of divalent cations, wall shear rate and platelet membrane glycoproteins. J Clin Invest. 1993;92:288-296.
35. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest. 1986;78:1456-1461.
36. Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, Anbo H, Kawai Y, Watanabe K, Itagaki I, Sakai, F, Ruggeri ZM. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest. 1991;87:1234-1240.
37. Kroll MH, Harris TS, Moake JL, Handin RI, Schafer AI. von Willebrand factor binding to platelet GpIb initiates signals for platelet activation. J Clin Invest. 1991;88:1568-1573.
38.
Chow TW, Hellums JD, Moake JL, Kroll MH. Shear
stress-induced von Willebrand factor binding to
platelet glycoprotein Ib initiates calcium influx
associated with aggregation. Blood. 1992;80:113-120.
39. Voorberg J, Fontijn R, Van Mourik JA, Pannekoek H. Domains involved in multimer assembly of von Willebrand factor (vWF): multimerization is independent of dimerization. EMBO J. 1990;9:797-803.[Medline] [Order article via Infotrieve]
40.
Sakariassen KS, Ottenhof-Rovers M, Sixma JJ.
Factor VIII-von Willebrand factor requires calcium for
facilitation of platelet adherence. Blood. 1984;63:996-1003.
41.
Aleviadou BR, Moake JL, Turner NA, Ruggeri ZM, Folie
BJ, Phillips MD, Schreiber AB, Hrinda ME, McIntire LV.
Real-time analysis of shear-dependent thrombus
formation and its blockade by inhibitors of von
Willebrand factor binding to platelets.
Blood. 1993;81:1263-1276.
42. Ruggeri ZM, DeMarco L, Gatti L, Bader R, Montgomery RR. Platelets have more than one binding site for von Willebrand factor. J Clin Invest. 1983;72:1-12.
43.
Rand JH, Sussman II, Gordon RE, Shu SV, Solomon
V. Localization of factor VIII-related antigen in human vascular
subendothelium. Blood. 1980;55:752-756.
44. Sussman II, Rand JH. Subendothelial deposition of von Willebrand's factor requires the presence of endothelial cells. J Lab Clin Med. 1982;100:526-532. [Medline] [Order article via Infotrieve]
45. Rand JH, Patel ND, Schwartz E, Zhou S-L, Potter BJ. 150-kD von Willebrand factor binding protein extracted from human vascular subendothelium is type VI collagen. J Clin Invest. 1991;88:253-259.
46. Rand JH, Wu X-X, Potter BJ, Uson RR, Gordon RE. Co-localization of von Willebrand factor and type VI collagen in human vascular subendothelium. Am J Pathol. 1993;142:843-850. [Abstract]
47. van Zanten GH, de Graaf S, Slootweg PJ, Heijnen HFG, Connolly TM, de Groot PG, Sixma JJ. Increased platelet deposition on atherosclerotic coronary arteries. J Clin Invest. 1994;93:615-632.
48. De Groot PG, Ottenhof-Rovers M, Van Mourik JA, Sixma JJ. Evidence that the primary binding site of von Willebrand factor that mediates platelet adhesion to subendothelium is not collagen. J Clin Invest. 1988;82:65-73.
49. Turitto VT, Weiss HJ, Baumgartner HR. Decreased platelet adhesion on vessel segments in von Willebrand's disease: a defect in initial attachment. J Lab Clin Med. 1983;102:551-564. [Medline] [Order article via Infotrieve]
50. Goldsmith HL, Turitto VT. Rheological aspects of thrombosis and haemostasis: basic principles and applications. Thromb Haemost. 1986;55:415-435. [Medline] [Order article via Infotrieve]
51.
Sobel M, Soler DF, Kermode JC, Harris RB.
Localization and characterization of a heparin binding domain peptide
of human von Willebrand factor. J Biol
Chem. 1992;267:8857-8862.
52. Sixma JJ, Schiphorst ME, Verweij CL, Pannekoek H. Effect of deletion of the A1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin. Eur J Biochem. 1991;196:369-375. [Medline] [Order article via Infotrieve]
53. Sobel M, McNeill PM, Carlson PL, Kermode JC, Adelman B, Conroy R, Marques D. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest. 1991;87:1787-1793.
54.
Lyons SE, Bruck ME, Bowie EJ, Ginsburg D.
Impaired intracellular transport produced by a subset of type IIA von
Willebrand disease mutations. J Biol
Chem. 1992;267:4424-4430.
55.
Lankhof H, Wu YP, Schiphorst ME, Zerwes H, De Groot PG,
Sixma JJ. Role of the GPIb-binding A1-repeat and the
RGD-sequence in platelet adhesion to recombinant von
Willebrand factor. Blood. 1995;86:1035-1043.
56. Tschopp TB, Baumgartner HR. Platelet adhesion and mural platelet thrombus formation on aortic subendothelium of rats, rabbits and guinea pigs correlate negatively with the vascular PGI2-production. J Lab Clin Med. 1981;98:402-411.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
K. Shim, P. J. Anderson, E. A. Tuley, E. Wiswall, and J. Evan Sadler Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress Blood, January 15, 2008; 111(2): 651 - 657. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-P. Wu, H. J. Bloemendal, E. E. Voest, T. Logtenberg, P. G. de Groot, M. F. B. G. Gebbink, and H. C. de Boer Fibrin-incorporated vitronectin is involved in platelet adhesion and thrombus formation through homotypic interactions with platelet-associated vitronectin Blood, August 15, 2004; 104(4): 1034 - 1041. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nishiya, M. Kainoh, M. Murata, M. Handa, and Y. Ikeda Reconstitution of adhesive properties of human platelets in liposomes carrying both recombinant glycoproteins Ia/IIa and Ibalpha under flow conditions: specific synergy of receptor-ligand interactions Blood, June 17, 2002; 100(1): 136 - 142. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Novak, H. Deckmyn, S. Damjanovich, and J. Harsfalvi Shear-dependent morphology of von Willebrand factor bound to immobilized collagen Blood, March 15, 2002; 99(6): 2070 - 2076. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Roest, J. D. Banga, D. E. Grobbee, P. G. de Groot, J. J. Sixma, M. J. Tempelman, and Y. T. van der Schouw Homozygosity for 807 T Polymorphism in {alpha}2 Subunit of Platelet {alpha}2{beta}1 Is Associated With Increased Risk of Cardiovascular Mortality in High-Risk Women Circulation, October 3, 2000; 102(14): 1645 - 1650. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Roest, J. J. Sixma, Y.-P. Wu, M. J. W. Ijsseldijk, M. Tempelman, P. J. Slootweg, P. G. de Groot, and G. H. van Zanten Platelet adhesion to collagen in healthy volunteers is influenced by variation of both alpha 2beta 1 density and von Willebrand factor Blood, August 15, 2000; 96(4): 1433 - 1437. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Estavillo, A. Ritchie, T. G. Diacovo, and M. A. Cruz Functional Analysis of a Recombinant Glycoprotein Ia/IIa (Integrin alpha 2beta 1) I Domain That Inhibits Platelet Adhesion to Collagen and Endothelial Matrix under Flow Conditions J. Biol. Chem., December 10, 1999; 274(50): 35921 - 35926. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Verkleij, L. F. Morton, C. G. Knight, P. G. de Groot, M. J. Barnes, and J. J. Sixma Simple Collagen-Like Peptides Support Platelet Adhesion Under Static But Not Under Flow Conditions: Interaction Via alpha 2beta 1 and von Willebrand Factor With Specific Sequences in Native Collagen Is a Requirement to Resist Shear Forces Blood, May 15, 1998; 91(10): 3808 - 3816. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Moroi, S. M. Jung, S. Nomura, S. Sekiguchi, A. Ordinas, and M. Diaz-Ricart Analysis of the Involvement of the von Willebrand Factor-Glycoprotein Ib Interaction in Platelet Adhesion to a Collagen-Coated Surface Under Flow Conditions Blood, December 1, 1997; 90(11): 4413 - 4424. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-P. Wu, P. G. de Groot, and J. J. Sixma Shear Stress–Induced Detachment of Blood Platelets From Various Surfaces Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 3202 - 3207. [Abstract] [Full Text] |
||||
![]() |
G. A. Barabino, R. J. Wise, V. A. Woodbury, B. Zhang, K. A. Bridges, R. P. Hebbel, J. Lawler, and B. M. Ewenstein Inhibition of Sickle Erythrocyte Adhesion to Immobilized Thrombospondin by von Willebrand Factor Under Dynamic Flow Conditions Blood, April 1, 1997; 89(7): 2560 - 2567. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |